X0306 4 2019-02-11 0 0001604464 Atara Biotherapeutics, Inc. ATRA 0001612095 Haqq Christopher 611 GATEWAY BOULEVARD SUITE 900 SOUTH SAN FRANCISCO CA 94080 0 1 0 0 EVP, R&D & Chief Scientific Of Common Stock 2019-02-11 4 S 0 13975 38.55 D 272718 D Common Stock 17312 I See footnote Common Stock 2688 I See footnote Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018. The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.27 to $38.55. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The shares are held by the Chris Haqq 2014 GRAT, of which the Reporting Person is trustee. The shares are held by The Havenside Trust, of which the Reporting Person is trustee. /s/ David Tucker, Attorney-in-Fact for Christopher Haqq 2019-02-11